What are the current challenges in ALL that need to be addressed?

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Selina M. Luger, University of Pennsylvania, Philadelphia, US. We asked: What are the current challenges in ALL that need to be addressed?

Here, she highlights a number of considerations regarding ALL treatment strategies:

1) Should all patients receive transplant for the treatment of ALL?

2) Do all patients with Philadelphia chromosome-positive ALL require intensive chemotherapy?

3) Are there patients with Philadelphia chromosome-negative ALL who demonstrate good responses without chemotherapy?

4) Should targeted agents be incorporated into chemotherapy regimens?

Selina M. Luger concludes by highlighting the lack of targeted agents available for T-cell ALL and outlines emerging therapeutics in this setting.